NCT03338426View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia

PHASE3CompletedINTERVENTIONAL
Enrollment

133

Participants

Timeline

Start Date

January 15, 2018

Primary Completion Date

April 22, 2019

Study Completion Date

April 22, 2019

Conditions
Essential Hypertension, Dyslipidemia
Interventions
DRUG

Fimasartan 120mg

Fimasartan 120mg will be administrated once daily for 8 weeks treatment period

DRUG

Atorvastatin 40mg

Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period

DRUG

Placebo for Fimasartan 120mg

Placebo for Fimasartan 120mg will be administrated once daily for 8 weeks treatment period

DRUG

Placebo for Atorvastatin 40mg

Placebo for Atorvastatin 40mg will be administrated once daily for 8 weeks treatment period

Trial Locations (1)

Unknown

Severance Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Boryung Pharmaceutical Co., Ltd

INDUSTRY

NCT03338426 - A Study to Evaluate the Efficacy and Safety of Combination Treatment of Fimasartan/Atorvastatin in Patients With Essential Hypertension and Dyslipidemia | Biotech Hunter | Biotech Hunter